Evidence map›Paper›PMID 36937885›Full record

ArticleFrontiers in pharmacology2023

The influence of

Kong Ling-Fei, Rong Xiao-Juan, Yan Pan, Qin Tuo, Zhang Xiao-Hui, Kang Yu-Tong, Cheng Bo, Su Wen-Ling, Gao Tian-Le, Tie Cai

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Antioxidants (Basel, Switzerland) · 2025
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Kong Ling-FeiState key laboratory Coal resources and Safe Mining, China University of Mining and Technology-Beijing, Beijing, China.
Rong Xiao-JuanXinjiang Institute of Material Medica, Urumqi, China.
Yan PanState key laboratory Coal resources and Safe Mining, China University of Mining and Technology-Beijing, Beijing, China.
Qin TuoState key laboratory Coal resources and Safe Mining, China University of Mining and Technology-Beijing, Beijing, China.
Zhang Xiao-HuiState Key laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China.
Kang Yu-TongXinjiang Institute of Material Medica, Urumqi, China.
Cheng BoXinjiang Institute of Material Medica, Urumqi, China.
Su Wen-LingXinjiang Institute of Material Medica, Urumqi, China.
Gao Tian-LeInstitute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Tie CaiState key laboratory Coal resources and Safe Mining, China University of Mining and Technology-Beijing, Beijing, China.
China University of Mining and Technology · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current drugs do not provide an absolute cure or modify the course of asthma.

Indexed as

asthmacytokinesHyssopus cuspidatus Boriss extract (SXCF)inflammationlipid mediators (LMs)

Identifiers

PMID36937885
PMCPMC10017864
OpenAlexW4322772861

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read2
measurements read58
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.